Anti-inflammatory and immunomodulatory activities of the extracts from the inflorescence of Chrysanthemum indicum Linne

被引:147
作者
Cheng, WM
Li, J [1 ]
You, TP
Hu, CM
机构
[1] Anhui Med Univ, Sch Pharm, Hefei 230032, Peoples R China
[2] Univ Sci & Technol China, Dept Chem, Hefei 230026, Peoples R China
关键词
Chrysanthemum indicum; anti-inflammation; immunomodulation; mononuclear phagocytosis;
D O I
10.1016/j.jep.2005.04.035
中图分类号
Q94 [植物学];
学科分类号
071001 [植物学];
摘要
Chrysanthemum indicum Linne (CI) has a long history for the treatment of inflammation, hypertension and respiratory diseases in China. The purpose of the present study was to investigate the anti-inflammatory and immunomodulatory properties of the inflorescence or bud of CI extracts. The ethanol extract of CI (CIEE) was fractionated to a petroleum ether soluble fraction (CIPF), an ethyl acetate soluble fraction (CIEF), a butanol soluble fraction (CIBF) and a water soluble fraction (CIWF) successively. CIBF (150 mg/kg, p.o.) caused a significant inhibition on the auricle edema in mice. CIBF (150, 300 mg/kg, p.o.) not only significantly increased the delayed-type hypersensitivity (DTH) reaction induced by 2,4-dinitro-fluorobenzene (DNFB) but also significantly enhanced antibody generation by splenic cells of mice and IgG and IgM levels in mice sera in response to sheep red blood cells (SRBC) in cyclophosphamide (CP)-induced mice. Furthermore, CIBF (150, 300 mg/kg, p.o.) obviously potentiated the function of the mononuclear phagocytic system in CP-induced mice. The above results reveal that CIBF possesses anti-inflammatory, humoral and cellular immunomodulatory and mononuclear phagocytic activities, probably due to the presence of flavonoids. (C) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:334 / 337
页数:4
相关论文
共 9 条
[1]
BIOZZI G, 1953, BRIT J EXP PATHOL, V34, P441
[2]
DING CH, 2001, EXPT METHODS PHARM P, P911
[3]
[林春蕊 Lin Chunrui], 2002, [广西植物, Guihaia], V22, P467
[4]
SHAO L, 2000, J SHENYANG PHARM U, V17, P133
[5]
SHEN YX, 2001, EXPT METHODS PHARM, P1433
[6]
Wang ZG., 2000, Chin J Trad Med Sci Tech, V2, P92
[7]
WEI W, 2001, EXPT METHODS PHARM, P1429
[8]
Xu SY, 1982, EXPT METHODS PHARM, P934
[9]
Yoshikawa M, 1999, CHEM PHARM BULL, V47, P340, DOI 10.1248/cpb.47.340